ArticleJournal of neuroinflammation2026
HMGB1-mediated endoplasmic reticulum stress in monocyte-derived dendritic cells regulates CD4+ T cell immune responses in myasthenia gravis.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionMyasthenia gravis (MG) is an autoimmune disorder characterized by immune dysregulation at the neuromuscular junction. Monocyte-derived dendritic cells (moDCs) are increasingly recognized as key drivers of MG pathogenesis; however, the mechanisms that govern their dysfunction remain incompletely understood.
methodsThis study integrated human genetics, patient immunophenotyping, and therapeutic evaluation in the experimental autoimmune myasthenia gravis (EAMG) model. Monocytes were isolated and differentiated into moDCs to assess the effects of HMGB1 and its inhibitor, 18α-glycyrrhetinic acid (18α-GA), on the expression profiles, phenotypes, and functions of moDCs. Therapeutic efficacy was further assessed in EAMG using 18α-GA, HMGB1 neutralizing antibody, and adoptive transfer of 18α-GA-induced tolerogenic moDCs.
resultsMendelian randomization (MR) analyses revealed bidirectional causality between MG and moDCs. MG patients exhibited elevated plasma HMGB1 levels and mature phenotypes of moDCs. Mechanistically, HMGB1 activated the IRE1α/XBP1 and NF-κB pathways in moDCs through the engagement of TLR4, thereby inducing endoplasmic reticulum (ER) stress, promoting the activation of moDCs, and driving an imbalance in CD4+ T cell immune responses. Through a multitargeted mechanism of action, 18α-GA effectively inhibited both the IRE1α/XBP1 and NF-κB pathways in moDCs, thereby blunting ER stress and driving the differentiation of moDCs toward tolerogenic phenotypes. The minimal effective dose of 18α-GA alleviated EAMG by counteracting HMGB1-driven, moDC-mediated CD4+ T cell dysfunction, and showed better therapeutic performance compared with HMGB1 neutralizing antibody. Moreover, the adoptive transfer of 18α-GA-induced tolerogenic moDCs was effective in treating EAMG.
conclusionsHMGB1-mediated ER stress reprogrammed moDCs via the IRE1α/XBP1 and NF-κB pathways to promote pathogenic CD4+ T cell responses in MG. Targeting the HMGB1-ER stress axis in moDCs could restore immune balance and represent a promising therapeutic strategy for MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.